Drug Profile

Lu 177 ethylenedicysteine-glucosamine - CellPoint

Alternative Names: ¹⁷⁷Lu-EC G; ¹⁷⁷Lu-Oncardia

Latest Information Update: 28 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CellPoint
Developer CellPoint; University of Texas M. D. Anderson Cancer Center
Class Diagnostic conjugates; Organometallic compounds; Radiopharmaceutical diagnostics; Radiopharmaceuticals
Mechanism of Action Apoptosis stimulants; Ionising radiation emitters; Single-photon emission-computed tomography enhancers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Mar 2024 No recent reports of development identified for preclinical development in Lung-cancer(Diagnosis) in USA
28 Feb 2024 No recent reports of development identified for preclinical development in Lung-cancer in USA
05 Feb 2020 CellPoint has 59 patent protection for Oncardia^®

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com